Company intelligence / Profile preview

Aevi Genomic Medicine

Wayne, Pennsylvania, United States

Ownership: Private
Employees: ~20
Development stage: Other

Overview

The company's lead candidate, AEVI-001 (fasoracetam), failed to meet the primary endpoint in a Phase 2 trial (SAGA study) for ADHD in patients with metabotropic glutamate receptor (mGluR) gene mutations. Following this, the company pivoted to AEVI-002, which demonstrated proof-of-concept in early trials for pediatric Crohn's disease prior to the company's acquisition.

Therapeutic areas: NeurologyGastroenterology
Modalities: Small moleculeMonoclonal antibody
Industry: Biotech

Partnerships

Children's Hospital of PhiladelphiaKyowa Kirin

Beyond the preview

Go deeper on Aevi Genomic Medicine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aevi Genomic Medicine.

Explore the full profile